Literature DB >> 23774134

Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats.

Andrew E Arrant1, Elizabeth Coburn, Jacob Jacobsen, Cynthia M Kuhn.   

Abstract

There has been controversy over use of selective serotonin reuptake inhibitors (SSRIs) to treat affective disorders in children and adolescents due to clinical reports of increased risk for suicidal ideation and behavior during treatment, and animal studies showing changes in adult anxiety- and depressive-like behaviors after repeated treatment during adolescence. However, the acute effect of serotonergic drugs on affective behavior during adolescence is poorly understood. We investigated serotonergic modulation of anxiety-like behavior in adolescent (PN28-32) and adult (PN67-73) male rats using the SSRI fluoxetine, the 5-HT(1A) agonist 8-OH DPAT, and the 5-HT₂ agonist mCPP. Acute treatment with fluoxetine (10 mg/kg, i.p.) produced greater anxiogenic effects in adults than adolescents in the light/dark (LD) test for anxiety-like behavior, but fluoxetine (2.5, 5, and 10 mg/kg, i.p.) increased extracellular serotonin in the medial prefrontal cortex similarly in both ages. Adults were also more sensitive to the anxiogenic effects of 8-OH DPAT (0.25 and 0.5 mg/kg, i.p.), but not mCPP (0.5 and 1 mg/kg, i.p.), in the LD test. Fluoxetine (10 mg/kg) stimulated greater increases in c-Fos expression across the extended amygdala in adults than in adolescents, and 8-OH DPAT (0.5 mg/kg) produced greater increases in c-Fos in the lateral orbital cortex and central nucleus of the amygdala in adults. These data show that lower anxiogenic effects of acute SSRIs in adolescents are associated with lesser activation of cortical and amygdala brain regions. This immaturity could contribute to the different profile of behavioral effects observed in adolescents and adults treated with SSRIs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adolescence; Anxiety; Microdialysis; Serotonin; c-Fos

Mesh:

Substances:

Year:  2013        PMID: 23774134      PMCID: PMC3812685          DOI: 10.1016/j.neuropharm.2013.05.030

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  70 in total

Review 1.  Self-harm and suicide in adolescents.

Authors:  Keith Hawton; Kate E A Saunders; Rory C O'Connor
Journal:  Lancet       Date:  2012-06-23       Impact factor: 79.321

Review 2.  Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.

Authors:  Christoph U Correll; Christopher J Kratochvil; John S March
Journal:  J Clin Psychiatry       Date:  2011-05       Impact factor: 4.384

3.  The postnatal ontogeny of monoamine-containing neurones in the central nervous system of the albino rat.

Authors:  L A Loizou
Journal:  Brain Res       Date:  1972-05-26       Impact factor: 3.252

4.  Inactivation of the dorsal raphé nucleus reduces the anxiogenic response of rats running an alley for intravenous cocaine.

Authors:  Aaron Ettenberg; Oren A Ofer; Carl L Mueller; Stephanie Waldroup; Ami Cohen; Osnat Ben-Shahar
Journal:  Pharmacol Biochem Behav       Date:  2010-11-23       Impact factor: 3.533

5.  Youth risk behavior surveillance - United States, 2011.

Authors:  Danice K Eaton; Laura Kann; Steve Kinchen; Shari Shanklin; Katherine H Flint; Joseph Hawkins; William A Harris; Richard Lowry; Tim McManus; David Chyen; Lisa Whittle; Connie Lim; Howell Wechsler
Journal:  MMWR Surveill Summ       Date:  2012-06-08

6.  Developmental changes in amphetamine-induced taste aversions.

Authors:  R N Infurna; L P Spear
Journal:  Pharmacol Biochem Behav       Date:  1979-07       Impact factor: 3.533

Review 7.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.

Authors:  Craig J Whittington; Tim Kendall; Peter Fonagy; David Cottrell; Andrew Cotgrove; Ellen Boddington
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

8.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

9.  Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid.

Authors:  W E Seifert; J L Foxx; I J Butler
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

10.  CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective.

Authors:  J F Leckman; D J Cohen; B A Shaywitz; B K Caparulo; G R Heninger; M B Bowers
Journal:  Arch Gen Psychiatry       Date:  1980-06
View more
  4 in total

1.  Withdrawal from Brief Repeated Alcohol Treatment in Adolescent and Adult Male and Female Rats.

Authors:  Weston Fleming; Quincy Jones; Upasana Chandra; Aashna Saini; David Walker; Reynold Francis; Gabriela Ocampo; Cynthia Kuhn
Journal:  Alcohol Clin Exp Res       Date:  2018-12-31       Impact factor: 3.455

2.  Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.

Authors:  Leslie R Amodeo; Venuz Y Greenfield; Danielle E Humphrey; Veronica Varela; Joseph A Pipkin; Shannon E Eaton; Jelesa D Johnson; Christopher P Plant; Zachary R Harmony; Li Wang; Cynthia A Crawford
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

3.  Brief Social Isolation in the Adolescent Wistar-Kyoto Rat Model of Endogenous Depression Alters Corticosterone and Regional Monoamine Concentrations.

Authors:  Reshma A Shetty; Monika Sadananda
Journal:  Neurochem Res       Date:  2017-02-24       Impact factor: 3.996

4.  Repeated Systemic Treatment with Rapamycin Affects Behavior and Amygdala Protein Expression in Rats.

Authors:  Martin Hadamitzky; Arne Herring; Julia Kirchhof; Ivo Bendix; Matthew J Haight; Kathy Keyvani; Laura Lückemann; Meike Unteroberdörster; Manfred Schedlowski
Journal:  Int J Neuropsychopharmacol       Date:  2018-06-01       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.